Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-306) of anti-HER2 biparatopic antibody-drug ...

SUZHOU, China, Feb. 6, 2025 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic ...

A thyroglobulin antibody (TgAb) test looks for certain antibodies that attack the thyroid. The presence of TbAb in high levels may indicate that someone has an autoimmune condition. To conduct a ...

Comparative outcomes of neuroendocrine tumors in the historically underserved population of Bronx, NY: Montefiore Einstein Comprehensive Cancer Center. Pamrevlumab ...

Mahindra BE 6 and XEV 9e, the first two EVs based on the automaker’s INGLO platform, have already been launched and its phase 1 test drives are already underway in cities such as Delhi ...

In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments.

Certain claudins can now be used as biomarkers to predict patient prognosis in a variety of solid cancers ... rapid translation of anti-CLDN18.2 antibodies from pre-clinical studies into clinical ...

Human epithelial growth factor receptor-2 (HER2) plays an oncogenic role in numerous tumors, including breast, gastric, and various other solid tumors ... The novel nanobody-based HER2-targeted ...

Immunotherapy has now joined cytotoxic chemotherapy as an effective systemic treatment for cancer, and antibody-based therapy has contributed most significantly to this burgeoning area.